Breast imaging has gone 3-D. The FDA announced today the approval of Hologic Inc.’s Selenia Dimensions System, the first X-ray mammography device that provides 3-D images for breast cancer screening and diagnosis.
Breast imaging has gone 3-D. The FDA announced today the approval of Hologic Inc.’s Selenia Dimensions System, the first X-ray mammography device that provides 3-D images for breast cancer screening and diagnosis.
“Physicians can now access this unique and innovative 3-D technology that could significantly enhance existing diagnosis and treatment approaches,” said Jeffrey Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health.
The device can provide two- and three-dimensional X-ray images of the breast, and the 3-D images may improve the accuracy of the detection and diagnosis of breast cancer, according to the FDA. The traditional 2-D imaging has its limitations, the FDA noted, and about 10 percent of women receive further testing after the initial screening for abnormalities later determined to be noncancerous.
The FDA reviewed results from two studies where radiologists reviewed 2-D and 3-D images from more than 300 mammography exams, according to the agency. Radiologists obtained a 7 percent improvement in their ability to distinguish between cancerous and noncancerous cases using the 3-D images, compared with 2-D.
“While the combination of the Selenia’s 2-D and 3-D images approximately doubled the radiation dose the patient received, it improved the accuracy with which radiologists detected cancers, decreasing the number of women recalled for a diagnostic workup,” the FDA said in a statement. “ There is uncertainty for radiation risk estimates; however, the increase in cancer risk from having both a 2-D and 3-D exam is expected to be less than 1.5 percent compared to the natural cancer incidence, and less than 1 percent compared to the risk from conventional 2-D mammography.”
Rob Cascella, Hologic’s president and CEO, said in a statement, "Our Dimensions 3-D takes advantage of all of the benefits of digital mammography and quite simply makes it better with the combination of fast, high quality 3-D breast imaging. We believe tomosynthesis has the potential to change how screening and diagnostic mammography is performed, and over time will prove invaluable to the earliest possible detection of breast cancer and in the reduction of unnecessary diagnostic interventions."
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
Study Says Contrast-Enhanced Mammography Offers Comparable Breast Cancer Detection to MRI
November 15th 2023In findings from an enriched cohort of asymptomatic patients with screening-detected abnormalities, researchers found that contrast-enhanced mammography (CEM) was superior to conventional mammography and offered equivalent detection of breast cancer in comparison to breast MRI and abbreviated breast MRI.